Overview

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
We hypothesize that successfully treating maternal Attention Deficit Hyperactivity Disorder (ADHD) will have a beneficial effect that extends to the child. We believe that multi-component interventions combining maternal stimulant medication, Lisdexamfetamine (LDX), and Behavioral Parent Training (BPT) will improve parenting, maternal, and child outcomes. In terms of improved parenting, we hypothesize that some mothers may respond well to LDX or BPT alone and therefore may not require multi-modal treatment, whereas others may benefit most from multi-modal treatment
Phase:
Phase 4
Details
Lead Sponsor:
Seattle Children's Hospital
Collaborator:
Shire
Treatments:
Lisdexamfetamine Dimesylate